Wave Life Sciences Advances Obesity Program, AATD Data Expected Soon
Event summary
- Wave Life Sciences reported Q1 2026 revenue of $38.2 million, compared to $9.2 million in the prior year.
- The FDA accepted the Phase 2a multidose portion of the INLIGHT trial for WVE-007, targeting obesity and related conditions, slated to begin in 2Q 2026.
- Data from the RestorAATion-2 trial for WVE-006 (AATD) will be presented at the ATS International Conference in May 2026, including data from 400mg and 600mg cohorts.
- Wave Life Sciences maintains $544.6 million in cash and cash equivalents, projecting a runway into 3Q 2028.
The big picture
Wave Life Sciences is betting heavily on its RNA therapeutics platform, PRISM®, to address significant unmet needs in obesity, rare diseases like AATD, and liver conditions. The company's progress with WVE-007, particularly the observed visceral fat reduction, positions it within a competitive landscape of obesity treatments, while WVE-006 offers a potential breakthrough for AATD patients. Success hinges on demonstrating clinical efficacy and navigating regulatory hurdles, all while managing a substantial R&D budget.
What we're watching
- Clinical Efficacy
- The Phase 2a INLIGHT trial results will be critical in determining whether WVE-007’s observed body composition changes translate to meaningful improvements in cardiometabolic health markers, and whether it can differentiate itself from incretin treatments.
- Regulatory Pathway
- The FDA’s feedback on the accelerated approval pathway for WVE-006 will significantly impact its commercialization timeline and potential revenue generation, particularly given the unmet need in AATD.
- Cash Management
- While Wave Life Sciences currently has a substantial cash runway, the ongoing clinical trials and potential for future acquisitions will necessitate careful management of resources to extend that runway.
Related topics